Facing mounting pressure to make an acquisition, Gilead executives were likely relieved to report an unexpected surge of second-quarter growth.
Roche's highly touted new multiple sclerosis drug Ocrevus surprised the market by generating $200 million in its first quarter on the market.
With the expanding definition of “health” in play, does the category warrant a separate show in a program like the Lions?
Will Mystic make it? That’s been the pressing question for AZ for months as the lung cancer trial proceeded. Answer: It didn’t, at least not yet.
J&J's Janssen unit will shell out up to $879 million to develop HIV and HBV vaccines using Bavarian Nordic's MVA-BN technology.
Eli Lilly’s RA med baricitinib had been pegged as one of 2017’s hottest launches—and a threat to Pfizer’s Xeljanz. Not anymore.
Thousands of FDA employees will get a reprieve instead of pink slips next week as FDA Commissioner Scott Gottlieb gave them encouraging job news.
Roche has sealed a deal to provide Gazyvaro to U.K. patients through the revamped Cancer Drugs Fund.
New CEO Emma Walmsley is putting her stamp on GSK with plans to get more from the pharmaceutical unit, which includes a major overhaul of R&D.
Specialists at rare disease drug launches, Cambridge BioMarketing was snapped up by an expansion-minded healthcare services firm, Ireland's UDG.
Amgen beat revenue expectations in second-quarter earnings released Tuesday, but some analysts think the company needs M&A. Its executives? Not so much.